Protekt Therapeutics Israeli Company

Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimers disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation.